Wall Street brokerages forecast that Kamada Ltd. (NASDAQ:KMDA) will announce earnings per share (EPS) of $0.07 for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Kamada’s earnings, with the lowest EPS estimate coming in at $0.04 and the highest estimate coming in at $0.10. Kamada reported earnings of $0.13 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 46.2%. The business is scheduled to report its next quarterly earnings results on Wednesday, February 10th.
On average, analysts expect that Kamada will report full-year earnings of $0.42 per share for the current fiscal year, with EPS estimates ranging from $0.39 to $0.44. For the next fiscal year, analysts anticipate that the business will post earnings of $0.11 per share, with EPS estimates ranging from $0.01 to $0.24. Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that that provide coverage for Kamada.
Kamada (NASDAQ:KMDA) last posted its earnings results on Wednesday, November 11th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.08 by $0.07. The firm had revenue of $35.33 million during the quarter, compared to analysts’ expectations of $33.49 million. Kamada had a net margin of 15.60% and a return on equity of 12.89%.
KMDA has been the subject of a number of analyst reports. BidaskClub lowered Kamada from a “sell” rating to a “strong sell” rating in a research report on Friday, October 9th. ValuEngine downgraded shares of Kamada from a “hold” rating to a “sell” rating in a report on Thursday, January 7th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $10.33.
A number of hedge funds and other institutional investors have recently modified their holdings of KMDA. Ritholtz Wealth Management increased its position in shares of Kamada by 17.2% during the 3rd quarter. Ritholtz Wealth Management now owns 34,276 shares of the biotechnology company’s stock valued at $287,000 after purchasing an additional 5,039 shares during the period. Bank of America Corp DE acquired a new position in Kamada during the second quarter worth about $56,000. O Shaughnessy Asset Management LLC raised its position in Kamada by 10.0% in the third quarter. O Shaughnessy Asset Management LLC now owns 85,892 shares of the biotechnology company’s stock worth $718,000 after acquiring an additional 7,825 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in Kamada in the 2nd quarter valued at about $84,000. Finally, Jane Street Group LLC boosted its position in shares of Kamada by 61.9% during the 3rd quarter. Jane Street Group LLC now owns 32,090 shares of the biotechnology company’s stock valued at $268,000 after purchasing an additional 12,268 shares in the last quarter. 14.72% of the stock is owned by hedge funds and other institutional investors.
KMDA traded up $0.02 during trading hours on Wednesday, hitting $7.06. The company’s stock had a trading volume of 138,355 shares, compared to its average volume of 169,877. The company has a 50-day simple moving average of $6.59 and a 200 day simple moving average of $8.01. The firm has a market capitalization of $314.31 million, a PE ratio of 14.71 and a beta of 1.12. Kamada has a fifty-two week low of $4.40 and a fifty-two week high of $13.33.
Kamada Company Profile
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.
Featured Article: What is the CAC 40 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.